Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
350
Employees350
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
350
Employees350

HALO Key Statistics

Market cap
8.43B
Market cap8.43B
Price-Earnings ratio
15.42
Price-Earnings ratio15.42
Dividend yield
Dividend yield
Average volume
1.51M
Average volume1.51M
High today
$74.40
High today$74.40
Low today
$71.31
Low today$71.31
Open price
$73.34
Open price$73.34
Volume
1.98M
Volume1.98M
52 Week high
$79.50
52 Week high$79.50
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $71.71. The company's market cap stands at 8.43B, with a P/E ratio of 15.42.

On 2026-01-31, Halozyme Therapeutics(HALO) stock traded between a low of $71.31 and a high of $74.40. Shares are currently priced at $71.71, which is +0.6% above the low and -3.6% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 1.98M, against a daily average of 1.51M.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $79.50 at its peak.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $79.50 at its peak.

HALO News

Simply Wall St 2d
Halozyme Acquisitions And Partnerships Sharpen Drug Delivery Growth Story

Halozyme Therapeutics (NasdaqGS:HALO) has acquired Surf Bio and Elektrofi to expand its drug delivery technology portfolio. The company has also broadened comm...

Halozyme Acquisitions And Partnerships Sharpen Drug Delivery Growth Story
Benzinga 2d
Halozyme Therapeutics Projects Sustained Growth Well Into 2040

Halozyme Therapeutics Inc. (NASDAQ:HALO) raised its 2026 and multi-year financial guidance, citing accelerating royalty revenue, expanding partnerships, and rec...

Halozyme Therapeutics Projects Sustained Growth Well Into 2040
TipRanks 3d
Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21

Sees FY26 revenue $1.71B-$1.81B, consensus $1.69B. Sees FY26 adjusted EBITDA $1.13B-$1.17B. Sees FY26 royalty revenue $1.13B-$1.17B. Torley added, “In the near-...

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

More HALO News

Simply Wall St 4d
How Takeda ENHANZE License Deal in IBD Will Impact Halozyme Therapeutics Investors

In January 2026, Takeda and Halozyme Therapeutics announced a global collaboration and exclusive license granting Takeda access to Halozyme’s ENHANZE drug-deliv...

How Takeda ENHANZE License Deal in IBD Will Impact Halozyme Therapeutics Investors

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.